Overview

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Studying samples of tumor tissue, blood, and urine in the laboratory from patients receiving erlotinib may help doctors predict how patients will respond to treatment. PURPOSE: The phase II trial is studying proteomic profiling to see how well it predicts response in patients receiving erlotinib for stage IIIB, stage IV, or recurrent non-small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Vanderbilt-Ingram Cancer Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Bevacizumab
Carboplatin
Erlotinib Hydrochloride
Paclitaxel